Dashboard
Financial statements
CRL

Company financials

Charles River Laboratories

Health Care Life Sciences Tools & Services Wilmington, Massachusetts Last filing Feb 18, 2026 · FY2025
Revenue FY2025
$4.0B
-0.9%
Net income FY2025
$-144.3M
-750.1%
Total assets FY2024
$7.5B
-8.1%
Operating cash flow FY2024
$22.2M
-95.3%

Balance Sheet

Assets, liabilities, and equity

33 accounts · 5 years
Total assets $7.5B
Total liabilities $4.0B
Shareholders equity $3.5B
Account 2025 2024 2023 2022 2021
Statement
BS Assets Cash $213.8M — — $233.9M —
BS Assets Accts Receivable $708.9M — — $752.4M —
BS Assets Inventory $299.1M — — $255.8M —
BS Assets Prepaid Expenses $129.2M — — $107.6M —
BS Assets Total Current $1.4B — — $1.4B —
BS Assets PPE $1.7B — — $1.5B —
BS Assets Op Lease ROU $361.4M — — $391.8M —
BS Assets Goodwill $2.8B — — $2.8B —
BS Assets Intangible Assets $340.0M — — $955.3M —
BS Assets LT Investments $207.0M — — $311.6M —
BS Assets Deferred Tax Assets $67.3M — — $41.3M —
BS Assets Other Noncurrent $293.2M — — $148.3M —
BS Assets Total $7.1B — — $7.6B —
BS Liab Accts Payable $148.8M — — $205.9M —
BS Liab Accrued Liab $270.1M — — $219.8M —
BS Liab Deferred Rev Current $210.4M — — $264.3M —
BS Liab Current Debt $166.0K — — $1.3M —
BS Liab Op Lease Current $3.2M — — $46.5M —
BS Liab Other Current $222.2M — — $204.6M —
BS Liab Total Current $1.1B — — $1.1B —
BS Liab Op Lease Noncurrent $434.0M — — $389.7M —
BS Liab Deferred Tax Liab $95.2M — — $215.6M —
BS Liab Other Noncurrent $138.3M — — $174.8M —
BS Liab Total $3.9B — — $4.6B —
BS Equity Preferred Stock $0 — — $0 —
BS Equity Common Stock $492.0K — — $509.0K —
BS Equity APIC $1.9B — — $1.8B —
BS Equity Retained Earnings $1.4B — — $1.4B —
BS Equity Treasury Stock $0 — — $0 —
BS Equity AOCI $-171.8M — — $-262.1M —
BS Equity NCI $5.3M — — $4.8M —
BS Equity Total $3.2B — — $3.0B —
BS Equity Total Liab and Equity $7.1B — — $7.6B —